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Abstract: The discovery of the physiological roles of nitric oxide has revolutionized the understanding of regulation of 
vascular tone, platelet adhesion and aggregation, and immune activation. Perhaps the most intriguing aspect of nitric oxide 
(NO) is that it is a gas that, in the absence of receptors, can regulate both normal physiological events and mediate cyto-
toxicity under pathological conditions. NO is produced from L-arginine by NO synthases (NOS), yielding L-citrulline and 
NO. The regulation of L-arginine pathway activity occurs at the level of NO production. The metabolic syndrome is a 
cluster of insulin resistance, elevated blood pressure, and atherogenic dyslipidemia, a common basis of cardiovascular 
disease. It occurs in genetically susceptible individuals with environmental influences and has serious economic and so-
cial consequences. Pharmacological and non-pharmacological therapies should be individualized and targeted to normal-
ize its alterations of blood pressure, HDL cholesterol, triglycerides and glucose values. Despite the increasing prevalence 
of the metabolic syndrome in the last decades, there has been little progress in the understanding of the precise mecha-
nisms involved in the pathogenesis of this syndrome and its complications. Emerging evidence is available that NO, in-
flammation and oxidative stress play important roles in the physiopathology of this syndrome. This review summarizes 
and evaluates the participation of the L-arginine-NO pathway and oxidative stress in the physiopathology of the metabolic 
syndrome and cardiovascular events at the systemic level, as well as the effects of exercise on this syndrome.  
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1. INTRODUCTION 
  Metabolic syndrome is characterised by glucose intoler-
ance, insulin resistance, abdominal adiposity, elevated blood 
pressure, and dyslipidaemia and is associated with increased 
morbidity and mortality, due at least in part to vascular com-
plications [1, 2]. 
  Recently, studies in animals and humans have suggested 
that endothelial-nitric oxide (NO)-mediated vasorelaxation is 
impaired and decreases the blood flow to skeletal muscle in 
metabolic syndrome [2]. NO exerts important vasodilatory, 
antiplatelet, antioxidant, antiadhesive and antiproliferative 
effects [3]. Inappropriate release of this mediator or impaired 
availability of its precursor L-arginine may contribute to the 
development of clinically significant atherosclerosis and 
increase the tendency for thrombus formation in this syn-
drome [2]. 
  In the present study, we review the current state of 
knowledge regarding the role of NO, endothelial dysfunction 
and oxidative stress in metabolic syndrome and the effects of 
exercise, a non-pharmacological tool. 
2.  METABOLIC SYNDROME: DEFINITION AND 
EPIDEMIOLOGY 
  The concept of metabolic syndrome has existed for at 
least 80 years. In the 1920s by Kylin, a Swedish physician,  
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as the clustering of hypertension, hyperglycaemia, and gout. 
Later, in 1947, Vague drew attention to upper body adiposity 
(android or male-type obesity) as the obesity phenotype that 
was commonly associated with metabolic abnormalities oc-
curring in type 2 diabetes and cardiovascular disease [4]. In 
1988, Reaven described syndrome X, which includes insulin 
resistance, hyperglycaemia, hypertension, low HDL-
cholesterol, and raised VLDL-triglycerides [5]. This syn-
drome is an intermediate state between normal metabolism 
and type 2 diabetes mellitus, and was subsequently called 
metabolic syndrome [6]. 
  The third report of the US National Cholesterol Educa-
tion Program (NCEP) Adult Treatment Panel III (ATP III) 
has provided a definition of the metabolic syndrome to aid in 
the diagnosis and treatment of patients at risk for chronic 
heart disease (CHD). The NCEP ATP III criteria require  3 
of the 5 risk factors listed in Table 1 [1]. 
Table  1.  The National Cholesterol Education Program's 
Adult Treatment Panel III (NCEP: ATP III , 2001) 
NCEP: ATP III,2001 
3 or more of the following: 
Central obesity: waist circumference >102 cm (male), >88 cm (female) 
Hypertriglyceridaemia: triglycerides 1·7 mmol/L 
Low HDL cholesterol: <1·0 mmol/L (male), <1·3 mmol/L (female) 
Hypertension: blood pressure 130/85 mm Hg or medication 
Fasting plasma glucose 6·1 mmol/L Nitric Oxide in Metabolic Syndrome  The Open Biochemistry Journal, 2008, Volume 2    109 
 Eckel  et al. [4] related that prevalence of metabolic syn-
drome is very age-dependent but is high in obese children 
and adolescents, and increases with worsening obesity. The 
prevalence of MS varies in urban populations from 8% (In-
dia) to 24% (USA) in men, and from 7% (France) to 43% 
(Iran) in women [4].  
  The NCEP ATP III suggests that metabolic syndrome is 
associated with the development of CHD. However, the level 
of risk associated with the syndrome is unclear. In a Finnish 
population-based, prospective cohort study, the risk for car-
diovascular disease mortality over a 12-year follow-up pe-
riod was clearly higher in subjects with metabolic syndrome 
versus those without [7]. The unadjusted RR of cardiovascu-
lar disease mortality was high at 3.55, suggesting that pa-
tients with metabolic syndrome may have as high a risk for 
cardiovascular disease mortality as patients with prior CHD 
[7].  
3. L-ARGININE TRANSPORT AND NITRIC OXIDE 
PRODUCTION 
  NO is generated, in mammalian cells, from the amino 
acid L-arginine using the enzyme nitric oxide synthase 
(NOS), with the same spectral characteristic as the cyto-
chrome P-450 family and an ED50 for L-arginine of about 6 
M [3, 8-10]. NO synthases include four prosthetic sets in 
their structure: flavin-adenine dinucleotide (FAD); flavin 
mononucleotide (FMN); tetrahydrobiopterin (H4  biopterin) 
and a haeme complex. The production of nitric oxide from 
L-arginine involves two monooxygenation steps requiring 
O2 and NADPH: an initial hydroxylation of L-arginine to 
generate N-hydroxyarginine and an oxidation leading to the 
formation of NO and citrulline [3, 8-10] (Fig. 1). 
  In mammals, all NOS derive from three genes. The three 
isoforms (neuronal) nNOS, (inducible) iNOS and (endothe-
lial) eNOS are differentiated according to their location, de-
pendence on increased cytosolic Ca2+ for their activity (> ~ 
100 nM), duration of action and the fact that iNOS is induc-
ible while the other two are constitutive [3, 8] (Table 2). Re-
cently, a NOS located in the mitochondria (mtNOS) has been 
observed in different brain regions, which is responsible for 
the production of NO in these organelles and identified as 
nNOS [11]. 
  Nitric oxide is a potent endogenous vasodilator that pre-
vents platelet adhesion and aggregation and inhibits vascular 
smooth muscle proliferation. Platelets themselves also pos-
sess nitric oxide synthases whose detailed structure has been 
identified [13]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). L-arginine-nitric oxide pathway. 
NO=nitric oxide; NOS=nitric oxide synthase; GC=guanylase cyclase; GTP=guanosine triphosphate; cGMP=cyclic guanosine monophos-
phate; ADMA=asymmetric dimethylarginine; L-NMMA. 
Table 2.  Summary of the Features of the Three NOS Isoforms  
  nNOS or type I  iNOS or type II  eNOS or type III 
First identification  neurones macrophages  Endothelium 
Molecular weight (kDa)  160 130 133 
Cromossomal localisation  12p24.2 17cen-q12  7q35-36 
Major function  Neuronal messenger  Immunocytotoxicity  Relaxation of VSM* 
Levels of NO produced  pmoles nmoles pmoles 
Regulation of expression  Constitutive 
Up-regulated by sex hormones, 
nerve and brain injury  
Not normally present 
Expression induced by cytokines 
and endotoxin 
Constitutive 
Up-regulated by sex hormones and 
shear stress 
*VSM=vascular smooth muscle.  
Refs. [3, 8-10, 12].  
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  The intracellular concentration of L-arginine is usually 
well above the Km for nitric oxide production (~3-4 mM in 
endothelial cells, macrophages and smooth muscle cells) 
[14]. However, under certain conditions, e.g. when endothe-
lial cells are placed in an L-arginine-free medium [15] or 
when L-arginine transport is inhibited with antisense nucleo-
tides to the transporter [16], NO production is diminished.  
  Humans synthesise L-arginine analogues, such as asym-
metric dimethylarginine (ADMA) and monomethyl-L-
arginine (L-NMMA), which are endogenous inhibitors of 
NOS and L-arginine transport that enhance platelet aggrega-
tion and increase blood pressure [17]. 
  NO activates soluble guanylate cyclase in the target tis-
sue binding to heme protoporphyrin to produce cGMP, 
which in turn phosphorylates cGMP-dependent protein 
kinase (PKG). PKG acts at several sites within the cell 
membrane and sarcoplasmic reticulum lowering intracellular 
Ca
2+ levels ([Ca
2+]i), dephosphorylaing myosin light chain, 
and also decreasing its Ca
2+ sensitivity [18]. As a result, 
there is a decrease vascular tone, since the phosphorylation 
of Ser-19 on the 20-kDa myosin regulatory light chains is the 
primary determinant of cross-bridge attachment and cycling 
during contraction and relaxation in smooth muscle [19]. 
The [Ca
2+]i decrease mediated by PKG can be explained by: 
(1) activation of PKG-dependent K
+-channel [20] and Ca
2+-
dependent K
+-channels [21] resulting in membrane hyperpo-
larization and inhibition of Ca
2+ entry through voltage-gated 
Ca
2+-channels in the cell membrane[22]; and (2) increased 
cellular extrusion of Ca
2+  via  activation of Ca
2+-ATPAse 
pumps and Na
+/Ca
2+ exchanger[23,24]. 
 Conversely,  [Ca
2+]i can also be reduced by an increase in 
cytosolic Ca
2+ uptake via  sarcoplasmic reticulum 
Ca
2+ATPase (SERCA) activation, a cGMP-independent 
pathway [25]. However, this action is not mediated by NO 
itself, but rather, by peroxynitrite after NO reaction with 
superoxide in physiological concentrations. SERCA is acti-
vated by reversible S-glutathiolation by peroxynitrite [26]. 
Thus, the response to authentic NO depends upon both 
cGMP-dependent inhibition of contractile proteins and 
cGMP-dependent and -independent decrease in intracellular 
free calcium levels that act cooperatively to relax smooth 
muscle and mediate vasodilation. 
4. THE PATHOPHYSIOLOGY OF METABOLIC 
SYNDROME: THE ROLE OF L-ARGININE-NITRIC 
OXIDE PATHWAY  
  The pathophysiology of the metabolic syndrome remains 
a subject of continuing controversy. There are studies sug-
gesting that insulin resistance is of central importance in this 
syndrome. One third of an apparently healthy population is 
sufficiently insulin resistant to develop significant clinical 
disease [27, 28].  Insulin resistance has traditionally been 
defined from a glucocentric view—i.e., when a defect in 
insulin action results in fasting hyperinsulinaemia to main-
tain euglycaemia [4]. Insulin has important vascular actions 
to stimulate production of NO in endothelium, leading to 
increased blood flow that contributes significantly to insulin-
mediated glucose uptake. Insulin signaling pathways in the 
vascular endothelium regulating production of NO share 
striking similarities with metabolic insulin signaling path-
ways in skeletal muscle and adipose tissue [29]. Defective 
insulin-stimulated endothelial release of NO appears to be 
responsible, in part, for impaired capillary network expan-
sion and the inability of insulin to redirect blood flow in the 
microcirculation towards metabolically active tissues (Fig. 
2). As a result, the diffusion of insulin and its metabolic sub-
strates is delayed and diminished, further aggravating the 
underlying insulin resistance. Moreover, the major factor in 
determining the rate of insulin transport across the capillary 
bed must be the size of the capillary bed itself or the inability 
of insulin to recruit previously closed capillary beds. In addi-
tion to insulin, adipocytokines and other endothelial products 
have been identified in insulin resistant obese individuals 
that are capable of altering capillary permeability, and thus 
could also interfere with the insulin’s metabolic action [30]. 
  In target tissues, insulin stimulates two major pathways: 
the phosphatidylinositol 3–kinase pathway and the mitogen-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects of metabolic syndrome in nitric oxide bioavailability. 
NO=nitric oxide; eNOS= endothelial nitric oxide synthase. 
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activated protein kinase (MAPK) pathway. The MAPK 
pathway has been shown also to regulate insulin-dependent 
endothelial NO production. In the presence of a defect in 
insulin-mediated glucose uptake, it has been demonstrated 
that there is also a defect in insulin-stimulated endothelial 
vasodilation. Thus, a systemic defect in the phosphatidyli-
nositol 3–kinase pathway, which likely defines insulin resis-
tance, leads to a combined defect in insulin-mediated glu-
cose transport and in insulin stimulated endothelial vasodila-
tion [31]. 
  A study by Michio Shimabukuro et al. [32] demonstrated 
in islets of rats predisposed to NIDDM (non–insulin-
dependent diabetes mellitus) that long-chain fatty acids in-
fluence pancreatic  cells via the NO system. In other tis-
sues, NO is thought to have a dual role, serving as a regula-
tor under physiologic conditions and as a cytotoxin under 
pathophysiologic ones. The cytotoxic role of NO can be in-
duced by FFA in islets of rats predisposed to NIDDM. It is 
possible that the higher NO levels in islets of Zucker Dia-
betic Fatty (ZDF) rats result in greater production of toxic 
hydroxyl ions from peroxynitrite. 
  Microvascular dysfunction is a cardinal feature of the 
metabolic syndrome that affects pressure and flow patterns, 
increasing peripheral vascular resistance and decreasing sen-
sibility for insulin-mediated glucose disposal, contributing to 
hypertension and insulin resistance, respectively [33]. In 
obese Zucker rats, an animal model of the metabolic syn-
drome, reduced endothelium-mediated dilation was associ-
ated with decreased NO bioavailability and excessive super-
oxide production [34]. Moreover, reduced skeletal muscle 
microvessel density (MVD) in this animal model seems to be 
a function of a chronic vascular reduction of NO [35]. In 
another animal model of the metabolic syndrome, chronic 
consumption of a high-fat diet by Fischer rats, the presence 
of endothelial dysfunction and oxidative stress, which can 
diminish NO bioavailability, was confirmed [36].  
  In patients with metabolic syndrome, responses to intra-
brachial acetylcholine were attenuated with no difference 
between normotensive and hypertensive groups [37]. NO 
level correlates with body mass index, systolic blood pres-
sure and triglycerides in these patients [38].  
  Studies indicate that vasodilatation, per se, does not in-
crease muscle glucose uptake. However, when vasodilatation 
occurs concomitantly with the recruitment of new capillary 
beds, as brought about by insulin, muscle glucose uptake is 
enhanced. In the same way that insulin resistance may con-
tribute to endothelial dysfunction, defects in NO-mediated 
vasodilation may contribute to insulin resistance [29, 30, 39].  
  Increased levels of ADMA, a competitive inhibitor of L-
arginine metabolism by transport and NO synthase, are asso-
ciated with endothelial dysfunction and increased cardiovas-
cular risk in various diseases [40]. Plasma levels of ADMA 
were positively correlated with insulin resistance in non-
diabetic, normotensive people [41]. However, ADMA was 
not found to be elevated in subjects with metabolic syn-
drome. Furthermore, no significant association between 
ADMA concentrations and the degree of insulin resistance 
was found in this group of patients [42]. 
  Adiponectin may exert some of its insulino-mimetic ac-
tions by stimulating phosphorylation and activation of eNOS 
in vascular endothelium, resulting in increased production of 
NO. Thus the novel role of adiponectin in eNOS activation, 
which explains both the metabolic and anti-atherogenic 
properties of adiponectin.[29].  
  Activation of the renin-angiotensin-aldosterone system 
(RAS)
 and subsequent elevations in angiotensin II and aldos-
terone,
 as seen in the metabolic syndrome, also contribute to 
altered insulin/IGF-1
 signaling pathways and reactive oxygen 
species formation to
 induce endothelial dysfunction and car-
diovascular disease. Several components of the RAS such as 
angiotensinogen, ACE (angiotensin-converting-enzyme), 
and angiotensin type 1 (AT1) receptors are present within 
human adipose tissue. Experimental studies suggest that the 
adipose RAS is regulated by hormonal and nutritional factors 
and correlates with the degree of obesity and that AII may 
modulate adipose tissue blood flow, growth, and metabo-
lism. Clinical trials with ACE inhibitors and Angiotensin 
Receptor Blockers (ARB) suggest that inhibition of the RAS 
alters glucose metabolism in humans. Thus, endothelial dys-
function can be reversed by short and long-term AT1 recep-
tor blockade. This cardioprotective effect is associated with 
increased NO bioavailability [6].  
  It has also been demonstrated that agents which improve 
endothelial function, an angiotensin-converting enzyme in-
hibitor and a statin, not only slowed the progression of CAD 
and occurrence of cardiovascular death but reduced the onset 
of type 2 diabetes in high-risk patients by approximately 
30% and 35%, respectively [31].  
  The thiazolidinediones are peroxisome proliferator-
activated receptor– agonists that improve glucose and 
lipid metabolism. These agents have recently been shown 
to improve endothelial function in the early stages of in-
sulin resistance [31]. 
  Aggressive pharmacological treatment of dyslipidemia 
and hypertension, even before the onset of MS, would 
appear prudent in decreasing the progression of the athe-
rosclerotic process [31]. So this can be the relationship 
among the molecular basis, insulin resistance, obesity, athe-
rosclerosis and other vascular complications of diabetes pre-
sent in the MS that need treatment. 
 Moreover, consumption of a Mediterranean-style diet by 
patients with the metabolic syndrome was associated with 
improvement of endothelial function and a significant reduc-
tion in markers of systemic vascular inflammation [43]. 
5. METABOLIC SYNDROME AND OXIDATIVE 
STRESS 
  Over the past decades, a great deal of research has been 
carried out to seek an understanding of the role of oxygen 
toxicity as well as reactive oxygen species (ROS) in a wide 
variety of pathological conditions [44]. A good deal of evi-
dence has emerged which demonstrates a close link among 
the metabolic syndrome, a state of chronic low-level in-
flammation and oxidative stress as second-level abnormali-
ties [45]. Experimental and clinical observations indicate 
oxidative stress as an important mechanism in hypertension, 
diabetes and obesity-associated metabolic syndrome and its 
complications [46, 47]. Excessive free radical production 
and oxidative damages appear to explain, at least in part, the 
perpetuation of insulin resistance, altered energy production, 112    The Open Biochemistry Journal, 2008, Volume 2  Assumpção et al. 
endothelial dysfunction and the appearance of vascular com-
plications in this condition. 
  A number of clinical studies have reported the impor-
tance of visceral fat accumulation in the development of 
metabolic disorders, including reduced glucose tolerance, 
hyperlipidemia and cardiovascular diseases. It is generally 
accepted that the sequence of events leading to hepatocyte 
fatty degeneration begins with insulin resistance, which pre-
cedes fat accumulation [48]. Excess intracellular fatty acids, 
oxidative stress, energy depletion and mitochondrial dys-
function then cause cellular injury [48-50]. 
  Hyperglycemia is the fundamental abnormality underly-
ing the mechanisms causing endothelial dysfunction in dia-
betes. In fact, hyperglycemia-induced ROS formation may 
successively lead to endothelial dysfunction by decreasing 
NO and prostacyclin bioavailability and by increasing the 
synthesis of vasoconstrictor prostanoids and endothelin [51]. 
In addition, the early and high incidence of atherosclerosis 
and cardiovascular events in patients with diabetes and post-
prandial high blood glucose levels has been partially associ-
ated with oxidative stress [52]. The inflammation associated 
with the atherosclerotic process is modulated by the activity 
of several families of enzymes, including cyclooxygenases, 
lipoxygenases, Nox, NO synthases and peroxidases — all 
possessing the capacity to produce ROS and NO species.  
  The participation of arterial hypertension in the genera-
tion of systemic oxidative stress associated with the meta-
bolic syndrome is suggested by a number of observations of 
the NO metabolism changes and the low circulating levels of 
vitamin C in patients with high-grade hypertension [53] and 
the improvement of systemic oxidative stress with antihyper-
tensive treatment [54]. Elevated levels of superoxide anion 
(O
-
2) and peroxinitrite (H2O2) are present in essential hyper-
tensive patients [55, 56]. Moreover, reduced antioxidant de-
fence mechanisms such as superoxide dismutase (SOD), 
catalase and glutathione peroxidase have been reported in 
blood cells and vessels from hypertensive patients and ex-
perimental hypertension [55, 57, 58]. These considerations 
have an even higher impact when associated with endothe-
lium activation and dysfunction as characterised by increased 
levels of circulating oxidised LDL, intercellular and vascular 
adhesion molecules and C-reactive protein [59], and with the 
evidence that vascular complications are also associated with 
oxidative stress events [60]. 
  Recent proposed mechanisms for hypertension develop-
ment in metabolic syndrome, attribute a central role to insu-
lin resistance and oxidative stress. It has been demonstrated 
that visceral adipose tissue produces and secrets a variety of 
bioactivity substances termed adipocytokines, such as leptin, 
tumor necrosis factor- (TNF-), interleukin-6 (IL-6), an-
giotensin II and non-esterified fatty acids (NEFA), which 
induce insulin resistance, oxidative stress and development 
of hypertension [61]. Insulin resistance seems to be the main 
pathophysiologic feature of the metabolic syndrome and 
some mechanisms connect insulin resistance with hyperten-
sion in this syndrome. The anti-natriuretic effect of insulin 
may be increased in individuals with insulin resistance and 
this effect may play an important role for development of 
hypertension. In vitro studies have shown that insulin stimu-
lates both endothelin-1 production and its action on the vas-
cular wall and induction of ROS. The renin-angiotensin sys-
tem (RAS) plays a crucial role in blood pressure regulation, 
by affecting function and by modulating vascular tone [62]. 
The activity of the RAS appears to be regulated by food in-
take, and overfeeding of rodents has been reported to lead to 
increased formation of angiotensin II in adipocytes [63]. 
Therefore, the alterations induced by insulin resistance may 
be amplified by increased angiotensin II levels that induce 
vasoconstriction, sodium retention, generation of ROS, re-
duced availability of NO and vascular damage inducing hy-
pertension. 
  Relatively new and interesting pathways of oxidative 
stress-induced vascular damages include enzymes such as 
Nox and homocysteine [64, 65]. Membrane-bound Nox is a 
major source of ROS in preatherosclerotic conditions and 
has been found in human peripheral and coronary arteries 
[66, 67]. Enhanced expression and activity of Nox enzymes 
have also been detected in new accumulated adipose tissue 
of obese mice and have been related to impaired antioxidant 
defence and adipocytokine dysregulation [46]. By increasing 
oxidative stress, activation of Nox in vascular cells has been 
reported to be an important mechanism in the pathogenesis 
of hypertension and atherosclerosis [68]. Angiotensin II is 
one of the most potent stimuli activating vascular Nox. This 
property clearly links ROS production with activation of the 
renin–angiotensin system in hypertension [69]. As a conse-
quence, drugs acting on the renin–angiotensin system reduce 
Nox activity, thus rendering this enzyme a specific drug tar-
get. 
6. EXERCISE AS A NON-PHARMACOLOGICAL 
THERAPY IN THE TREATMENT OF METABOLIC 
SYNDROME 
  Lifestyle changes, including an increase in physical ac-
tivity, are recommended for the treatment of metabolic syn-
drome [70]. There is an extensive body of knowledge regard-
ing the beneficial effects of physical activity on metabolic 
risk factors and atherosclerotic cardiovascular disease [71]. 
Exercise training, especially endurance exercise, has been 
shown to decrease body mass and visceral fat accumulation, 
improve insulin sensitivity, and decrease triglyceride levels 
and systolic and diastolic blood pressure [72, 73]. Higher 
plasma levels of HDL cholesterol after exercise training is 
not a consistent finding, since some studies show a decrease 
in these levels in metabolic syndrome patients. However, it 
is important to highlight that there is an improvement in the 
protective capacity of HDL against LDL oxidation [74], and 
a reduction in the LDL/HDL ratio [75]. These favourable 
changes can occur independent of changes in dietary energy 
intake [76]. Besides exerting positive effects on its individ-
ual features, exercise training can either prevent or treat 
metabolic syndrome itself. The prevalence of this syndrome 
is lower among those with higher physical activity and fit-
ness level [77], and it was observed that after 20 weeks of 
endurance training, 30.5% of 105 subjects were no longer 
classified as having metabolic syndrome in the HERITAGE 
Family Study [72].  
  In animal model studies, moderate intensity endurance 
training has been shown to enhance endothelium-dependent 
vasodilation via NO, since the enhanced relaxations to ACh 
were abolished by L-NAME, an L-arginine analogue that 
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clooxygenase, and preconstriction with KCl [78, 79]. Endur-
ance training also seems to be effective in preventing the 
reduction of microvessel density in the exercising muscle 
resulting from improved NO bioavailability and an altered 
profile of inflammatory markers associated with angiogene-
sis, such as monocyte chemoattractant protein-1 and IL-1 
[80].  
  Similar findings were observed in humans [74]. Meta-
bolic syndrome patients were submitted to daily endurance 
training at 70 to 85% of the maximal heart rate combined 
with a high-fibre, low-fat diet. After 3 weeks of training, 
besides an improvement in the lipid and metabolic profile, 
there was a decrease in oxidative stress, assessed by serum 
measurements of 8-isoprostaglandin F2 and myeloperoxi-
dase, and an increase in NO production in cultured human 
aortic endothelial cells. Exercise and a high-fibre, low-fat 
diet also resulted in reduced inflammation, endothelial cell 
and platelet activation, monocyte adhesion and monocyte-
chemotactic activity, and MMP-9, a marker of plaque deses-
tabilization. One interesting finding was that this improve-
ment occurred independent of weight loss.  
  Endurance exercise has also been shown to improve insu-
lin sensitivity in humans [73] and animals [81]. Following 2 
weeks of exercise training, obese Zucker rats presented an 
enhancement of insulin action on skeletal muscle glucose 
transport activity, primarily in the exercised musculature 
[81]. The mechanisms responsible for this change are still 
unknown, although training induces an increase in GLUT 4 
protein expression and in the activity of enzymes involved in 
glucose metabolism, such as hexokinase and citrate synthase 
[81]. Exercise also augments insulin-mediated glucose trans-
port in skeletal muscle and the expression of insulin receptor 
substrate (IRS)-1 protein and IRS-1-p85 interaction, suggest-
ing an improvement in the insulin stimulation of the IRS-
1/PI 3-kinase pathway. 
  Part of these changes may also be attributed to the low 
levels of adiponectin in metabolic syndrome patients, the 
most abundant adipokine secreted by adipocytes. Adi-
ponectin acts through two receptors, AdipoR1 and AdipoR2, 
which are primarily expressed in skeletal muscle and the 
liver, respectively [82], and both are also present in endothe-
lial cells [83, 84]. Chang et al. [85] demonstrated that 8 
weeks of aerobic exercise increased the mRNA and protein 
content of AdipoR1 in the exercised skeletal muscle of OZR, 
associated with an improvement in insulin sensitivity, as-
sessed by a glucose-insulin index (the product of the areas 
under the curve of glucose and insulin) during an intraperi-
toneal glucose tolerance test. This is an important finding, 
since adiponectin is involved in the sensitivity modulation by 
stimulating glucose utilisation and fatty acid oxidation via 
the phosphorylation and activation of AMPK in both muscle 
and liver cells [86, 87]. It is important to highlight that adi-
ponectin has also emerged as a cardioprotective adipokine 
that possesses antiatherogenic, and anti-inflammatory prop-
erties due to NO bioavailability modulation. In vitro, adi-
ponectin induces NO production in human aortic endothelial 
cells  via  activation of the AMPK pathway and enhanced 
endothelial eNOS RNA protein expression [88, 89]. Moreo-
ver, adiponectin suppresses superoxide generation and en-
hances eNOS activity in endothelial cells treated with oxi-
dised LDL [83].  
  When thinking of a "cardioprotective" polypill as sug-
gested by Wald and Law in 2003 [90], it is not possible to 
ignore the important role that physical activity plays in dif-
ferent cardiovascular risk factors. Although the precise 
mechanisms responsible for its benefits are still largely un-
known, endurance training was shown to reduce circulating 
levels of inflammatory markers and oxidative stress, and 
increase NO bioavailability  
7. CONCLUSION 
  Although comprehension of the complex multiorgan sys-
tem derangements that compose the metabolic syndrome has 
improved over the years, a reasonable understanding of the 
defects in specific cellular and sub-cellular functions has not 
been completely attained. Studies have indicated that meta-
bolic syndrome is characterised by abnormal regulation of 
NO synthesis by pancreatic and adipocytes cells and at the 
systemic level associated with increased oxidative stress. 
Growing evidence suggests that endurance exercise, a non-
pharmacological tool, can have a favourable impact on the 
metabolic alterations by reducing circulating levels of in-
flammatory markers and oxidative stress, and increasing NO 
bioavailability, therefore diminishing the risk of any cardio-
vascular event. 
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